 |
PDBsum entry 4c7t
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
|
|
Title
|
|
Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-Tumor and anti-Angiogenic activities.
|
|
|
Authors
|
|
P.Dao,
R.Jarray,
N.Smith,
Y.Lepelletier,
J.Le coq,
D.Lietha,
R.Hadj-Slimane,
J.P.Herbeuval,
C.Garbay,
F.Raynaud,
H.Chen.
|
|
|
Ref.
|
|
Cancer Lett, 2014,
348,
88-99.
[DOI no: ]
|
|
|
PubMed id
|
|
|
|
|
|
Abstract
|
|
|
FAK and FGFR2 signaling pathways play important roles in cancer development,
progression and tumor angiogenesis. PHM16 is a novel ATP competitive inhibitor
of FAK and FGFR2. To evaluate the therapeutic efficacy of this agent, we
examined its anti-angiogenic effect in HUVEC and its anti-tumor effect in
different cancer cell lines. We showed PHM16 inhibited endothelial cell
viability, adherence and tube formation along with the added ability to induce
endothelial cell apoptosis. This compound significantly delayed tumor cell
growth. Together, these data showed that inhibition of both FAK and FGFR2
signaling pathways can enhance anti-tumor and anti-angiogenic activities.
|
|
|
|
|
|
|
